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Abstract
Background: The choroid plexus consists of highly differentiated epithelium and functions as a
barrier at the interface of the blood-cerebrospinal-fluid (CSF). This tissue may therefore determine
the bioavailability and transport of drugs to the brain. Little is known about the expression of drug
and xenobiotic metabolizing enzymes (DME) and of drug transporters in the human choroid plexus.
Notably, the transcription factor and zinc finger protein HNF4alpha is a master regulator of DMEs
and of drug transporters. As of today its activity in the blood-CSF barrier is unknown. Here we
report our efforts in determining HNF4alpha activity in the regulation of ABC transporters in the
human and rat choroid plexus.
Results: We report expression of HNF4alpha by qRT-PCR and by immunohistochemistry and
evidence transcript expression of the ATP-binding cassette transporters ABCB1, ABCB4, ABCC1-
6 in choroid plexus. Additionally, HNF4alpha DNA binding activity at regulatory sequences of
ABCB4 and ABCC1 was determined by EMSA bandshift assays with a specific antibody. We then
performed siRNA mediated functional knock down of HNF4alpha in Caco-2 cells and found
ABCC1 gene expression to be repressed in cell culture experiments.
Conclusion: Our study evidences activity of HNF4alpha in human and rat choroid plexus. This
transcription factor targets DMEs and drug transporters and may well determine availability of
drugs at the blood-CSF barrier.
Background
Drug delivery to the brain is mediated by several factors,
most notably transport across the blood brain (BB) and
the choroid plexus barrier; the latter displays drug-metab-
olizing enzyme and drug transport activity. It may there-
fore determine the overall cerebral bioavailability of drugs
[1]. Specifically, the choroid plexus is located within brain
vesicles. It is composed of a tight monolayer of polarized
epithelial cells and forms the blood-cerebrospinal-fluid
(CSF) barrier. Together with the blood-brain barrier,
formed by endothelial cells of brain capillaries, it func-
tions as the main interface between the central nervous
system (CNS) and the peripheral circulation. Within the
CNS this tissue is of great pharmacological interest, but
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information on the expression of efflux transporters such
as the ATP binding cassette (ABC) proteins is missing [2].
In contrast, their expression in liver, kidney, and intestine
has been studied in considerable detail [3-5]. Indeed, the
ABC drug transporters extrude a variety of structurally
diverse drugs, drug conjugates and metabolites in an
active, ATP-dependent manner and even against high con-
centration gradients. The three main ABC families consid-
ered to be involved in the disposition of xenobiotics
include the ABCB family (MDR subfamily, multidrug
resistance, e.g. ABCB1/MDR1), the ABCC family of multi-
drug resistance proteins (MRP subfamily, multidrug
resistance related proteins, e.g. ABCC2/MRP2), and the
breast cancer resistance protein (ABCG2/BCRP) of the
ABCG family [3,4]. However, comprehensive studies on
the expression levels of ATP transporters in the human
choroid plexus have not been attempted.
Notably, there is clear evidence for HNF4a to play a role
in the transcriptional control of drug transporters. Specif-
ically, HNF4a is a member of the nuclear receptor super-
family and one of the key players in liver biology [6-8].
Among the genes regulated by HNF4a are a broad range
of xenobiotic-metabolizing cytochrome P450 isozymes
[9,10], UDP-glucuronosyltransferases [11], sulfotrans-
ferases [12] and transporters including organic anion
transporter 2 [13], organic cation transporter 1 [14], the
ABC transporter ABCC2 [15], ABCC6 [16], ABCG5 [17]
and  ABCG8  [17]. Although there is clear evidence for
HNF4a to be of key importance in the control of drug
metabolism it may also play a role in the regulation of
transporters in the choroid plexus. Here we report our
efforts in mapping HNF4a to human and rat choroid
plexus. We determined HNF4a DNA binding activity and
searched for transcript expression of various ABCB and
ABCC transporters in the human choroid plexus. Apart
from qRT-PCR and immunohistochemistry studies we
evidence ABCC1 gene expression to be highly dependent
on HNF4a as determined in functional knock down stud-
ies. Overall, we provide evidence for HNF4a t o  b e  a n
important regulator of ABC drug transporters in the
choroid plexus and thus may impact efficacy of pharma-
cotherapy targeted to the brain.
Results
Initially, we searched for HNF4a transcripts in individual
samples of human and rat choroid plexus and confirmed
gene expression of HNF4a by quantitative real time RT-
PCR (Figures 1A). We found HNF4a transcript expression
in human and rat choroid plexus to account for approxi-
mately a tenth of its expression in the liver (Figures 1A). It
is of considerable importance that HNF4a expression in
the human and rat choroid plexus is restricted to P1 pro-
moter driven isoforms (Table 1). Furthermore, we studied
expression of the insulin-like growth factor 2 (IGF2), tran-
sthyretin (TTR) and the transcription factor FOXJ1 to fur-
ther qualify choroidal epithelial cells of the brain [18,19].
These transcripts are specifically enriched in choroid
plexus. We observed abundant expression of IGF2, TTR
and FOXJ1 in human choroid plexus as compared to total
brain RNA extracts (Figures 1B). There is the need to study
histological well qualified tissue, as studies with total
brain RNA extracts would render findings meaningless as
will be discussed later on. Unfortunately, sufficient
human choroid plexus tissue suitable for the harvest of
nuclear protein and to perform western blotting as well as
EMSA assay could not be obtained. We nonetheless dem-
onstrate HNF4a protein expression by immunohisto-
chemistry by use of a specific HNF4a antibody for human
(Figures 2A) and rat choroid plexus (Figures 2C). To con-
firm specificity an excess of antigen preabsorbed to the
antibody was used (Figures 2B, D).
We then analyzed expression of different members of the
ABCB (MDR subfamily, multidrug resistance)/ABCC
(MRP subfamily, multidrug resistance related) gene fami-
lies in the human choroid plexus by quantitative real time
RT-PCR and report results for n = 3 individual human
choroid plexus samples. mRNA expression of ABCB4
(MDR2/3), ABCC1 (MRP1), ABCC2 (MRP2), ABCC3
(MRP3), ABCC4 (MRP4), ABCC5 (MRP5) and ABCC6
(MRP6) was comparable to its expression level in com-
mercially available control total human brain RNA
extracts (Figures 1C). mRNA expression of ABCB1
(MDR1) determined in choroidal epithelium was lower
than in human liver (n = 4) and in brain (Figures 1C).
We then searched for HNF4a binding sites in proximal
promoter sequences (up to -7000 bp) of drug transporter
coding genes. For this purpose, we used two different bio-
informatic approaches (see Material and Methods section
Table 1: HNF4a isoform expression in human and rat choroid 
plexus.
Patient HNF4aP1 HNF4aP2
Patient 100-04 0.0342 0
patient 44-04 0.0025 0
patient 62-04 0.4110 0
Animal HNF4aP1 HNF4aP2
rat 1 0.097 0
rat 2 0.348 0
rat 3 0.158 0
HNF4aP1 and P2 gene expression was measured in human and rat 
choroid plexus (n = 3, respectively) by real-time quantitative RT-PCR 
and computed relative to expression of mitATPase6, which served as 
a housekeeping gene. Patient characteristics are given in Table 5. 
Caco-2 cells and pancreatic tissue served as controls for HNF4aP2 
expression in human and rats, respectively.BMC Molecular Biology 2009, 10:68 http://www.biomedcentral.com/1471-2199/10/68
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for a description of the employed algorithms). We
observed three binding sites within the ABCB4 promoter,
spaced approximately by 600 bp and 1600 bp and two
recognition sites within the ABCC1 promoter (Table 2).
Predicted binding sites were confirmed by EMSA band
shift assays. We used 32P-labeled double-stranded DNA
probes to specifically probe for HNF4a-sites located in the
human ABCB4 (hABCB4_1, hABCB4_2 and hABCB4_3)
and in the human ABCC1 (hABCC1_1, hABCC1_2) gene.
Note, DNA binding of nuclear extracts to the A-site of the
HNF1a-promoter (HNF1pro) served as a positive control.
This site is an established recognition site for HNF4a.
Unfortunately, sufficient amount of human choroid
plexus suitable for the isolation of nuclear protein could
not be obtained. Instead, we used nuclear extracts isolated
from the human intestinal cell line Caco-2 which
expresses several ABC transporter genes [20] and therefore
is a rich source of HNF4a nuclear protein. Indeed, HNF4a
protein expression in Caco-2 cells is comparable to organs
such as the liver [21]. As depicted in Figures 3A we
observed strong binding of HNF4a to the A-site of the
HNF1a-promoter. We also observed strong binding of
Gene expression of HNF4a and different ABC transporters in the choroid plexus Figure 1
Gene expression of HNF4a and different ABC transporters in the choroid plexus. Gene expression of HNF4a and 
different ABC transporters in the choroid plexus. A: HNF4a gene expression in human (n = 3) and rat choroid plexus (n = 3) 
was measured by quantitative real-time RT-PCR and determined relative to expression of mitATPase6, which served as a 
housekeeping gene. Expression levels were compared to liver and total brain. Mean values + SD are shown. B and C: Gene 
expression of FOXJ1, IGF2 and TTR (B) and of different members of the ABCB and ABCC family (C) was analyzed in human 
choroid plexus by quantitative real-time RT-PCR and determined relative to expression of mitATPase6, which served as a 
housekeeping gene. Expression levels were compared to liver (n = 4) and total brain. Mean values + SD are shown.
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HNF4a to the predicted sites in the promoters of ABCB4
and ABCC1 (Figures 3A); bands could be shifted with a
specific HNF4a antibody therefore demonstrating selec-
tivity and specificity of the assay. Alignment of human, rat
and mouse ABCB4  and  ABCC1  genes did not identify
common HNF4alpha binding sites. This points to differ-
ences in the molecular organization of ABC promoters in
orthologous genes. HNF4alpha binding sites for the rat
and mouse ABCB4 and ABCC1 genes are given in Table 2,
whereas the sequences of oligonucleotides to confirm the
predicted sites experimentally are shown in Table 3. As
shown in Figures 3B and 3C EMSA band shift assays con-
firmed binding of HNF4a to rat and mouse ABCB4 and
ABCC1 targeted sequences.
To further probe for the role of HNF4a in ABC gene regu-
lation we employed an siRNA approach. Specifically,
siRNA-mediated functional knock down of HNF4a in the
Immunohistochemical detection of HNF4a in the choroid plexus Figure 2
Immunohistochemical detection of HNF4a in the choroid plexus. Slices of human (A, B) and rat (C, D) choroid 
plexus probes were stained with polyclonal antibodies against HNF4a. Arrows indicate representative HNF4a positive cells (A, 
C). To confirm specificity of the immunohistochemical localization antibodies were preabsorbed with excess of antigens for 
HNF4a (B, D). Patient identification numbers were indicated respectively and patient characteristics are given in Table 5. Mag-
nification ×400.
H55
H54 H54
H55
H40 H40
H5 H5
B competition A HNF4α
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human Caco-2 cell line resulted in significantly decreased
gene expression of ABCC1 (Table 4; for transfection effi-
ciency and stable expression of mitATPase6 after transfec-
tion see Niehof and Borlak, 2008 [22]). These results
confirm ABCC1 to be a gene target of HNF4a. ABCB4
expression in Caco-2 cells is near the limit of detection.
Consequently, knockdown experiments are not meaning-
ful.
Discussion
Our study aimed for a better understanding of the role of
HNF4a in the regulation of drug transporters. Here we
present evidence for expression of HNF4a in the epithe-
lium of the CSF barrier. By applying position weight
matrices to genomic sequences of ABC transporters we
were able to predict HNF4a binding sites in the promoters
of the ABCB4 and ABCC1 gene. The predicted binding
sites were then confirmed by EMSA band shift assays. We
propose a role for HNF4a in the regulation of drug trans-
Table 2: Predicted binding sites for HNF4a in ABC genes.
Gene name Accession number bp relative to transcription start site Score core/matrix
Human
ABCB4 NM_000443.3 -6274 to -6252 V$zemlin13_11045 1.000/0.896
-4680 to -4658 V$HNF4_01 1.000/0.990
V$zemlin13_1104 1.000/0.997
-4063 to -4041 V$HNF4_01 1.000/0.954
V$zemlin13_11045 1.000/0.958
ABCC1 NM_004996.3 -1756 to -1734 V$HNF4_01 0.915/0.925
-5266 to -5244 V$HNF4_01 1.000/0.944
V$zemlin13_11045 1.000/0.969
Rat
ABCB4 NM_012690.1 -4584 to -4562 V$zemlin13_11045 1.000/0.894
-39 to -17 V$HNF4_01 1.000/0.943
V$zemlin13_11045 1.000/0.978
ABCC1 NM_022281.2 -2146 to -2124 V$HNF4_01 1.000/0.908
Mouse
ABCB4 NM_008830.2 -5281 to -5259 V$zemlin13_11045 1.000/0.907
ABCC1 NM_008576.2 +2626 to +2648 (Intron 1) V$HNF4_01 1.000/0.924
V$zemlin13_11045 1.000/0.910
Transfac matrix (V$HNF4_01) or self-generated matrix (V$zemlin13_11045) with a setting of core and matrix similarity 0.9 was used.
Table 3: Shift-probes sequences.
Gene Oligo name Sequence
Human
HNF1a HNF1pro AGGGCTGA AGTCCA A AGTTCA GTCCCTTC
ABCB4 hABCB4_1 (GS49) AGAA AGGTCA A AGGCAA AGCA
hABCB4_2 (GS50) GTGC AGGGCA A AGGTCA GATT
hABCB4_3 (GS51) GCTA AGTCCA A AGATCA ATTC
ABCC1 hABCC1_1 (GS48) TTGAC AGTATA A AGGTCA AGCAA
hABCC1_2 (GS171) TTCAT AGAGCA A AGTACA GCAAC
Rat
ABCB4 rABCB4_1 (GS166) AGAAG CCCTCA A AGTCCA CCTAT
rABCB4_2 (GS167) CGCAG CGAGCA A AGTCCA GGTCT
ABCC1 rABCC1_1 (GS169) GACAC GGGCCA A AGACCC ACAGA
Mouse
ABCB4 mABCB4_1 (GS168) ATAGC CATGCA A AGTCCA AAAGA
ABCC1 mABCC1_1 (GS170) TCCCT TGTGCA A AGGTCT AGGAT
The central five nucleotides of the HNF4a binding site are highlighted in bold letters. The two direct repeats (DR1) separated by a spacer of one 
nucleotide are underlined.BMC Molecular Biology 2009, 10:68 http://www.biomedcentral.com/1471-2199/10/68
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HNF4a binding to promoters of ABCB4 and ABCC1 Figure 3
HNF4a binding to promoters of ABCB4 and ABCC1. Electrophoretic mobility shift assays with 2,5 mg Caco-2 cell 
nuclear extract and oligonucleotides corresponding to the A-site of the HNF1a promoter (HNF1pro) and to putative HNF4a 
binding-sites within human (A), rat (B) and mouse (C) ABCB4 and ABCC1 as 32P labeled probe. In supershift assays an antibody 
directed against HNF4a (+) was added. For oligonucleotide sequence information see Table 2 and 3.
HNF4α antibody -+
hABCC1_1 hABCB4_2
-+
hABCB4_3
-+
hABCB4_1
-+
HNF1pro
-+
HNF4α
supershifted
HNF4α
-+
hABCC1_2
rABCB4_2
-+
rABCC1_1
-+
rABCB4_1
-+
mABCC1_1
-+
mABCB4_1
-+ HNF4α antibody
HNF4α
supershifted
HNF4α
A
BC
Table 4: Functional knock down of HNF4a in cultures of human Caco-2 cells.
Gene Gene expression 48 h after HNF4a siRNA transfection [%] p-value*
HNF4a 24.0 0.0031
ABCC1 56.4 0.0478
Functional knock down of HNF4a was already reported [22]. * A student's t test was done to compare HNF4a siRNA transfection against negative 
siRNA transfected controls. The results were considered significant when the p value was less than 0.05. Gene expression was determined by real-
time quantitaive RT-PCR in triplicates; mitATPase6 served as housekeeping gene. The DDCT-method was used to determine repression of gene 
expression. Values for HNF4a siRNA transfection represent transcript abundance relative to negative siRNA transfected controls, which were set 
to 100%.BMC Molecular Biology 2009, 10:68 http://www.biomedcentral.com/1471-2199/10/68
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porters of the choroid plexus. Notably, HNF4a is a key
player in the regulation of genes coding for various meta-
bolic pathways and of xenobiotic metabolism [6-
9,23,24]. This protein also promotes expression of an epi-
thelial phenotype [25-27]. Specifically, epithelium of the
choroid plexus cells is highly differentiated and functions
as a blood-CSF barrier. The expression of HNF4a in the
epithelium of the choroid plexus and its DNA binding to
regulatory sequences of drug transporters is a novel find-
ing. Its expression accounts for approximately a tenth of
HNF4a expression found in liver. Furthermore, there is
evidence for HNF4a to undergo alternative splicing with
isoforms may arising from alternative splicing and/or
usage of two different promoters [6]. Specifically, the P1
promoter generates six different isoforms (HNF4a1-a6);
but activation of the P2 promoter results in isoforms
HNF4a7-a9. P2 promoter-driven HNF4a isoforms are
expressed throughout mouse liver development, but dis-
appear after birth, while P1 promoter-driven transcripts
are abundantly expressed postnataly [28]. Additionally,
P2 isoforms are induced in mouse and human hepatocel-
lular carcinoma [29,30] and are primarily expressed in
human pancreatic islets and exocrine cells [31]. In the case
of the choroid plexus it appears that expression of HNF4a
is restricted to P1 promoter-driven isoforms. HNF4a pro-
tein expression in human and rat choroid plexus could be
clearly evidenced by immunohistochemistry. To further
qualify tissue preparations of choroid plexus expression of
IGF2, TTR and FOXJ1 was investigated; their expression
are accepted genetic markers of the choroid plexus
[18,19]. We validated tissue preparations by morphologi-
cal and genetic markers. Unlike previous studies where
expression of HNF4a transcripts could not be evidenced
in total RNA extracts of the brain [6], we were able to con-
firm expression of HNF4a in the choroid plexus of human
and rat brain. Most certainly, total brain RNA extracts
Table 5: Patient characteristics.
Liver
Patient Identification Sex Age Information Tissue Application
P29 F 40 Colorectal liver metastasis Healthy tissue from liver 
resection
Gene expression analysis, 
comparison to choroid plexus
P2 F 70 Hepatocellular carcinoma Healthy tissue from liver 
resection
Gene expression analysis, 
comparison to choroid plexus
P3 F 57 Hepatocellular carcinoma Healthy tissue from liver 
resection
Gene expression analysis, 
comparison to choroid plexus
P4 M 67 Hepatocellular carcinoma Healthy tissue from liver 
resection
Gene expression analysis, 
comparison to choroid plexus
Choroid Plexus
Patient Identification Sex Age Cause of death Tissue Application
44-04 F 63 liver cirrhosis 38 h post mortem Gene expression analysis
62-04 F 79 ovarial carcinoma 33 h post mortem Gene expression analysis
100-04 M 74 Acute myocardial infarction 48 h post mortem Gene expression analysis
H5 M 53 Circulatory failure, liver cirrhosis Choroid plexus Paraffin-embedded slices for 
immunohistochemistry
H40 M 32 Circulatory failure, endocarditis Choroid plexus Paraffin-embedded slices for 
immunohistochemistry
H54 M 59 Respiratory insufficiency, 
pneunomia
Choroid plexus Paraffin-embedded slices for 
immunohistochemistry
H55 M 81 Circulatory failure, generalized 
artheriosclerosis
Choroid plexus Paraffin-embedded slices for 
immunohistochemistryB
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Table 6: Real-time PCR primer sequences and amplification settings.
Gene Accession number Species Primer sequence Fragment length Annealing Extension Fluorescence Slope
HNF4a NM_000457 human fwd:CTGCTCGGAGCCACCAAGAGATCCATG 371 bp 60°C 15 sec 88°C -3.629
rev: ATCATCTGCCAGGTGATGCTCTGCA
HNF4aP1 NM_178849 human fwd: GAATGCGACTCTCCAAAACC 339 bp 68°C 14 sec 88°C -3.058
NM_178850 rev: GGCACTGGTTCCTCTTGTCT
NM_000457
HNF4aP2 NM_001030003 human fwd: GGGCTCCAGTGGAGAGTTC 342 bp 68°C 14 sec 88°C -2.648
rev: CATAGCTTGACCTTCGAGTGC
FOXJ1 NM_001454 human fwd: CTACTCGTATGCCACGCTCA 183 bp 60°C 8 sec 86°C -3.459
rev: CGAGGCACTTTGATGAAGC
IGF2 NM_000162 human fwd: GGTGCTTCTCACCTTCTTGG 298 bp 68°C 12 sec 90°C -2.724
rev: GGGGTATCTGGGGAAGTTGT
TTR NM_000371 human fwd: CAGAAAGGCTGCTGATGACA 261 bp 60°C 11 sec 86°C -3.438
rev: GCCGTGGTGGAATAGGAGTA
ABCB1 NM_000927 human fwd: AAAAAGATCAACTCGTAGGAGTG 161 bp 60°C 7 sec 81°C -3.331
rev: GCACAAAATACACCAACAA
ABCB4 NM_000443 human fwd: CCACAGCGAACTGATGAAGA 301 bp 68°C 13 sec 83°C -3.826
rev: CACGACAAAGTAGGGCCATT
ABCC1 NM_004996 human fwd: AGTCCCCACAGAAGGAGTGG 358 bp 60°C 15 sec 87°C -3.639
rev: TCCCCGACCGTGGAGGATTT
ABCC2 NM_000392 human fwd: CCGTATCAGGTTTGCCAGTT 312 bp 60°C 13 sec 84°C -3.756
rev: CAACAGCCACAATGTTGGTCB
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ABCC3 NM_003786 human fwd: CTCAATGTGGCAGACATCGG 177 bp 60°C 8 sec 87°C -3.731
rev: GGGAGCTCACAAACGTGTGC
ABCC4 NM_005845 human fwd CTTGGAGAGGAGTTGCAAGG 236 bp 68°C 10 sec 78°C -4.479
NM_001105515 rev: GCTGTGTTCAAAGCCACAGA
ABCC5 NM_005688 human fwd: CCTGTTTGGGAAGGAATATGA 203 bp 60°C 9 sec 88°C -3.446
rev: CCTGTTTGGGAAGGAATATGA
ABCC6 NM_001171 human fwd: TTCTCTGTGTCGCTGGTGTC 309 bp 60°C 13 sec 87°C -2.982
rev: GGCACTGTGTATGGTGATGC
MitATPase6 NC_001807 human fwd: CTAAAGGACGAACCTGA 315 bp 55°C 13 sec 83°C -3.608
rev: TGGCCTGCAGTAATGTT
HNF4a NM_022180 rat fwd: GCCTGCCTCAAAGCCATCAT 274 bp 55°C 11 sec 88°C -3.697
rev: GACCCTCCAAGCAGCATCTC
HNF4aP1 D10554, EF193392 rat fwd: AAATGTGCAGGTGTTGACCA 178 bp 60°C 7 sec 87°C -3.296
rev: CACGCTCCTCCTGAAGAATC
HNF4aP2 AF329936 rat fwd: CTCCAGTGGCGAGTCCTTAT 171 bp 60°C 7 sec 87°C -2.273
EF193390 rev: TCACGCTCCTCCTGAAGAAT
MitATPase6 NC_001665 rat fwd: CTAAAGGACGAACCTGA 315 bp 55°C 13 sec 83°C -3.644
rev: TGGCCTGCAGTAATGTT
Table 6: Real-time PCR primer sequences and amplification settings. (Continued)BMC Molecular Biology 2009, 10:68 http://www.biomedcentral.com/1471-2199/10/68
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dilute copy number of HNF4a transcripts to presumable
levels below the limit of detection. Here, we evidence
binding of HNF4a to regulatory sequences of drug trans-
porters expressed in the choroid plexus and analyzed gene
expression of ABC transporters in patients with different
causes of death, but the functional significance of the
newly identified HNF4a binding sites in activating the
ABCB4 and ABCC1 promoters still needs to be estab-
lished.
In the past attempts to detect HNF4a DNA binding in a
choroid plexus papilloma failed [32]. The investigators
performed EMSA experiments with nuclear extracts of rat
liver, kidney and intestine and of SV40-induced choroid
plexus papilloma of transgenic mice, but unfortunately
probed for HNF4alpha binding with an oligonucleotide
corresponding to the HNF4a binding site in the mouse
TTR (transthyretin) promoter. The authors did not
employ an antibody in EMSA band shift assays; instead,
competition with excess of unlabeled probes was done.
Although the authors described a weak binding of HNF4a
with nuclear extracts from kidney they considered intes-
tine as well as choroid plexus as deficient for HNF4a bind-
ing. There is a need to consider tissue specific DNA
binding activity. HNF4a binding at the TTR promoter is
much less as compared to the A-site in the HNF1 pro-
moter (not exceeding a tenth, data not shown). As
detailed above, HNF4a gene expression in human and rat
choroid plexus is approximately one tenth of its expres-
sion in the liver (see Figures 1A). It is therefore not surpris-
ing that previous investigators [32] failed to detect HNF4a
protein in intestine and choroid plexus, even though the
authors described weak expression of this protein in kid-
ney. By now, it is well established that HNF4a expression
is not restricted to liver, but also functions in kidney and
intestine [33,34]. Here we evidence by immunohisto-
chemical staining HNF4a to be expressed in epithelium of
human and rat choroid plexus (see Figures 2).
Notably, the choroid plexus functions as a barrier for drug
uptake to the brain. This tissue expresses drug metaboliz-
ing enzymes (DMEs) and some transporters [1]. Expres-
sion of DMEs in the choroid plexus is part of a defense
program to prevent entry of xenobiotics into the brain.
The blood-CSF barrier also regulates entry and distribu-
tion of various pharmacologically active compounds
between the blood and the CSF interface and is basically
involved in numerous exchange processes thereby deter-
mining the supply of the brain with nutrients and hor-
mones [1]. Indeed, endogenous metabolites, as well as
neurotransmitter and metabolites from the brain are
cleared via this barrier [19]. In drug therapies efflux trans-
porters of the ABC-family are of pivotal importance in
determining therapeutic tissue levels. In the past research
focused on their regulation in liver, kidney and intestine
[3,4]. The knowledge on drug transporter in specialized
tissues of the brain is incomplete. Specifically, ABCB
(MDR) proteins accept a broad range of substrates and
may transport large lipophilic, neutral or cationic com-
pounds. This includes a vast number of neuropharmaco-
logical drugs such as antiepileptic and antiviral drugs,
antidepressants, opiods, antipsychotics and tranquilizer
[35-40]. ABCB1, a transporter with highest expression in
the gastrointestinal tract [4,41], is expressed at low levels
in human choroid plexus, that is much lower than in liver
and total brain. Our findings are consistent with results
reported previously for rats [42]. Its apical expression in
rat, mouse and human choroidal epithelium was shown
previously [43]. Furthermore, ABCB4 is highly expressed
in the liver, where it is acting as a "flippase" in transport-
ing phospholipids into the bile, but ABCB4 can also bind
and transport a subset of ABCB1 substrates with an over-
lap in substrate specificity [44]. As reported for ABCB1,
ABCB4  is expressed at low levels in human choroid
plexus, i.e. more than 500 fold lower than in liver. Low
ABCB4 expression was also evidenced in choroidal epithe-
lium of the rat [42], but to the best of our knowledge our
study is the first report on expression in human choroid
plexus. An apical distribution of ABCB1 in neonatal cul-
tured rat choroid plexus cells imply a drug transport from
blood into CSF [43]. In endothelial cells of small blood
capillaries of the blood-brain barrier, apical located
ABCB1 pumps drugs back into the blood stream and
therefore limits drug penetration to the brain [2].
Likewise, the ABCC (MRP) proteins are multispecific
organic anion transporters and accept glucurono-, glu-
tathione- and sulfo-conjugates. They transport physiolog-
ical substrate conjugates as well as drug conjugates.
Expression of ABCC1-6 mRNA transcripts was reported
for rat choroid plexus [42] as was expression of ABCC1 for
human choroid plexus [43,45,46]. ABCC1, ABCC4 and
ABCC5 were expressed in human choroid plexus at least
at 10 fold higher than in liver; whereas ABCC2, ABCC3
and ABCC6 were expressed up to 800 fold lower than
liver. Similar results were reported for ABCC transporter
expression in rat choroid plexus [42]. Notably, ABCC1 is
localized at the basolateral membrane of choroid plexus
[43,45,46], but Gazzin et al [46] described a major differ-
ence in the localization of ABCB1 and ABCC1 proteins
between the blood-brain and the blood-CSF barrier with
strongest expression of ABCC1 at the choroidal epithe-
lium. Indeed, ABCC proteins contribute to the protective
role of the choroid plexus and mediate basolateral efflux
of conjugates resulting from choroidal drug metabolism
into the blood. Although it is known that the choroid
plexus is important in regulating the distribution of vari-
ous pharmacologically active compounds between the
blood and the CSF, the characterization of the involved
human ABC transporters gives new insights into the func-
tion of the CSF barrier.BMC Molecular Biology 2009, 10:68 http://www.biomedcentral.com/1471-2199/10/68
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Furthermore, ABCBs (MDRs) and ABCCs (MRPs) are
inducible transporters and are highly responsive to chem-
otherapeutics, carcinogens, inflammation, heat shock,
hypoxia and irradiation [47]. They are regulated by a com-
plex network of transcriptional cascades, such as by mul-
tiple ligand activated nuclear receptors like retinoid X
receptor (RXR), farnesoid X receptor (FXR), constitutive
androstane receptor (CAR) and the xenobiotic receptor
pregnane X receptor (PXR) [47,48]. There is also evidence
for the transcription factors AP-1, p53, Egr-1 and WT-1 to
participate in their regulation with NF-Y, Sp1 and Sp3
being involved in the constitutive expression [47].
Recently, an upregulation of ABCB1, ABCB4 and ABCC4
transcripts was reported in human embryonic kidney cells
that conditionally expressed wild-type HNF4a [33]. An
important role of HNF4a in the transcriptional control of
drug transporters was reported for human hepatocytes as
determined by adenoviral HNF4a-siRNA mediated
knockdown [49]. We also employed an siRNA mediated
functional knockdown of HNF4a and found ABCC1 gene
expression to be massively repressed. There is a need to
improve an understanding of the mechanism by which
transporters are regulated. This will impact the design of
novel CNS therapeutics. Targeting transporters may thus
be useful in achieving therapeutic tissue levels of CNS
drugs.
Conclusion
We report expression of HNF4a in choroid plexus of the
human and rat brain. This factor might regulate expres-
sion of some ATP binding cassette transporters. Targeting
of HNF4a may impact efficacy of pharmacotherapy of
CNS drugs.
Methods
Human and rat tissue
A total of n = 7 human and n = 7 rat tissues were analyzed.
Samples of human choroid plexus (n = 3, gene expression
analysis) were kindly provided by T. Arendt (Department
of Neuroanatomy, Paul-Flechsig-Institute, University of
Leipzig, Germany). Paraffin-embedded slices of human
choroid plexus for immunohistochemistry (n = 4) were
kindly provided by C. Grothe (Institute of Neuroanatomy,
Hannover Medical School, Hannover, Germany). Human
liver tissue (gene expression analysis) was obtained from
patients undergoing hepatic resections and were kindly
provided by J. Klempnauer (Department of Visceral and
Transplantation Surgery, Hannover Medical School, Han-
nover, Germany). Patient characteristics are given in Table
5. Control human brain RNA was purchased from BD Bio-
sciences (Heidelberg, Germany).
Samples of rat choroid plexus (n = 3, Sprague Dawley rats,
gene expression analysis) were kindly provided by H.
Hilbig and K. Spanel-Borowski (Department of Anatomy,
University of Leipzig, Germany). Samples of rat liver and
brain (Sprague Dawley rats, gene expression analysis)
were generated in-house. Paraffin-embedded slices of rat
brain (Sprague Dawley rats) containing choroid plexus
regions for immunohistochemistry (n = 4) were kindly
provided by C. Grothe (Institute of Neuroanatomy, Han-
nover Medical School, Hannover, Germany).
Quantitative real-time RT-PCR
Analysis of human samples: Three human choroid plexus
samples and four human liver samples were analyzed sep-
arately and used for calculation of the mean and standard
deviation. Analysis of rat samples: Three rat choroid
plexus samples, three rat liver and three rat brain samples
were analyzed separately and used for calculation of the
mean and standard deviation. Total RNA from choroid
plexus and liver was isolated using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufactur-
ers recommendations. Subsequently to RNA isolation, a
DNase I digest was performed. 4 mg total RNA from each
sample was used for reverse transcription (Omniscript
Reverse Transcriptase, Qiagen, Hilden, Germany). Quan-
titative real-time RT-PCR measurement was done with the
Lightcycler (Roche Diagnostics, Mannheim, Germany)
with the following conditions: denaturation at 95°C,
annealing at different temperatures for 8 sec, extension at
72°C for different times and detection of SYBR-Green I-
fluorescence at different temperatures. Detailed primer
specific conditions and oligonucleotide sequence infor-
mation are given in Table 6. Relative quantification was
performed using the "Fit Points Method" of the
LightCycler3 Data Analysis Software version 3.5.28
(Roche Diagnostics, Mannheim, Germany) by comparing
the sample values to a standard curve within the linear
range of amplification. This comparison was performed
during each LightCycler Run (for genes of interest as well
as for the housekeeping gene, i.e. mitATPase6). The stand-
ardized sample values for each gene of interest were
divided by the standardized values of the housekeeping
gene. The slope of external standard curves are given in
Table 6, indicating the PCR efficiency for each amplicon.
Caco-2 cell culture
Caco-2 cells are a valuable source for HNF4a nuclear pro-
tein [21] and were obtained from and cultivated as recom-
mended by DSMZ (Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH, Braunsch-
weig, Germany) and seeded with a density of 4 × 106 cells
per 75 cm2 flask and harvested after 11 days of culture.
Isolation of nuclear extracts
Nuclear extracts from Caco-2 cells were isolated by the
modified method of Dignam et al [50]. Eleven days after
seeding cells were washed twice with ice-cold PBS, scraped
into microcentrifuge tubes and centrifuged for 5 min atBMC Molecular Biology 2009, 10:68 http://www.biomedcentral.com/1471-2199/10/68
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2000 × g, 4°C. Cell pellets were resuspended in lysis
buffer (10 mM Tris pH 7.4, 2 mM MgCl2, 140 mM NaCl,
1 mM DTT, 4 mM Pefabloc, 1% Aprotinin, 40 mM b-glyc-
erophosphate, 1 mM sodiumorthovanadate and 0.5%
TX100) at 4°C for 10 min (300 ml for 1 × 107 cells), trans-
ferred onto one volume of 50% sucrose in lysis buffer and
centrifuged at 14000 × g and 4°C for 10 min. Nuclei were
resuspended in Dignam C buffer (20 mM Hepes pH 7.9,
25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 1 mM DTT, 4 mM Pefabloc, 1% Aprotinin, 40 mM
b-glycerophosphate, 1 mM sodiumorthovanadate, 30 ml
for 1 × 107 cells) and gently shaked at 4°C for 30 min.
Nuclear debris was removed by centrifugation at 14000 ×
g at 4°C for 10 min. Protein concentrations were deter-
mined according to the method of Smith et al [51]. The
extracts were aliquoted and stored at -70°C.
Electrophoretic mobility shift assays
Forward and reverse oligonucleotides (for sequence infor-
mation see Table 3) were purchased from MWG Biotech
(Ebersberg/Muenchen, Germany), annealed and 32P-
labeled using 32PgATP and T4-kinase (New England
Biolabs, Frankfurt, Germany). 2,5 mg Caco-2 cell nuclear
extract and 105 cpm (0.027 ng) radiolabeled probe were
incubated in binding buffer consisted of 25 mM HEPES,
pH 7.6, 5 mM MgCl2, 34 mM KCl, 2 mM DTT, 2 mM Pefa-
bloc, 2% Aprotinin, 40 ng of poly (dI-dC)/ml and 100 ng
of bovine serum albumin/ml for 20 minutes on ice. Free
DNA and DNA-protein complexes were resolved on a 6%
polyacrylamide gel (acrylamide: bisacrylamide ratio =
37.5:1). Super shift experiments were done with a 1 mg
HNF4a specific antibody (sc-6556x, Santa Cruz Biotech-
nology, Heidelberg, Germany). DNA binding of nuclear
extracts to the A-site of the HNF1a-promoter (HNF1pro)
served as a positive control.
Bioinformatic searches for HNF4a binding-sites
The transcription start site (TSS, +1) of the NCBI mRNA
reference sequence (RefSeq) was aligned using the UCSC
Genome Browser http://genome.ucsc.edu/ for promoter
annotation of the respective genes. Proximal promoters
(up to -7000 bp) of human ABCB1, ABCB4 and ABCC1 to
ABCC6 were checked for putative HNF4a binding-sites
with the tool MATCH [52], http://www.biobase.de by
employing two different weight matrix, i.e. V$HNF4_01,
Transfac matrix (generated by Biobase) and V$zemlin13-
11045 (self-generated). V$zemlin13-11045 is based on a
collection of 33 well known HNF4a sites and was gener-
ated using the matrix generation tool of Biobase http://
www.biobase.de. At least one of both matrices has to
exceed the cut-off of 0.9 for core similarity and 0.9 for
matrix similarity (Table 2). Furthermore, proximal pro-
moters (up to -7000 bp) of rat and mouse ABCB4 and
ABCC1 were checked for putative HNF4a binding sites
(Table 2).
Immunohistochemistry
The sections were deparaffinized, demasked by heating,
incubated with 0,6% H2O2 in methanol for 30 min, and
subsequently with protein block serum-free reagent
(Dako, Glostrup, Denmark) for 10 min. Incubation with
polyclonal antibody (Santa Cruz Biotechnology, Heidel-
berg, Germany) against HNF4a (sc-6556x, 1:400 dilution
for rat sections, 1:200 dilution for human sections) was
performed for 45 min. The sections were rinsed with Tris-
buffered saline, incubated with biotinylated universal sec-
ondary antibodies (Dako, Glostrup, Denmark) for 15 min
and subsequently with horseradish peroxidase-conju-
gated streptavidin solution (Dako, Glostrup, Denmark)
for 15 min. Labeling was detected using a diaminobenzi-
dine (DAB) chromogen solution (Dako, Glostrup, Den-
mark) for 5 min. The sections were counterstained with
hematoxylin before examination under light microscope.
To confirm the specificity of the immunohistochemical
localization, antibodies preabsorbed 2 h with a twenty
fold excess of antigen for HNF4a (sc-6556P, Santa Cruz
Biotechnology, Heidelberg, Germany) were used.
siRNA silencing of HNF4a
Human HNF4a-specific siRNA probes were purchased
from Qiagen (Hilden, Germany). Caco-2 cells (1,5 × 105
cells/well in 24-well plate) were transfected in triplicate
for 48 h with 25 nM of the siRNA duplex using HiPerFect
transfection reagent (Qiagen, Hilden, Germany). Alexa-
Fluor488 labeld siRNA (Qiagen, Hilden Germany) was
used as negative siRNA and as positive control for trans-
fection efficiency. For transfection efficiency and stable
expression of mitATPase6 after transfection see Niehof
and Borlak, 2008 [22].
Abbreviations
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EMSA: electrophoretic mobility shift assay; HNF: hepato-
cyte nuclear factor; MDR: multidrug resistance gene fam-
ily (ABCB); MRP: multidrug resistance related proteins
gene family (ABCC); TTR: transthyretin.
Authors' contributions
JB designed the entire study, supervised the experimental
works and is responsible for the final writing of the man-
uscript, MN supervised the experiments and prepared the
initial draft of the manuscript. Both authors read and
approved the final manuscript.
Acknowledgements
We thank S. Marschke, A. Pfanne and A. Schulmeyer for valuable technical 
assistance, S. Reymann and R. Zemlin for assistance in bioinformatics and 
advice on design of PCR primers, T. Arendt, U. Gärtner and C. Grothe for 
providing samples of human choroid plexus and H. Hilbig, K. Spanel-
Borowski and C. Grothe for the preparation of rat choroid plexus. This BMC Molecular Biology 2009, 10:68 http://www.biomedcentral.com/1471-2199/10/68
Page 13 of 14
(page number not for citation purposes)
work was supported by a grant of the Lower Saxony Ministry of Culture 
and Science to J.B.
References
1. Ghersi-Egea JF, Strazielle N: Brain drug delivery, drug metabo-
lism, and multidrug resistance at the choroid plexus.  Microsc
Res Tech 2001, 52:83-88.
2. Graff CL, Pollack GM: Drug transport at the blood-brain barrier
and the choroid plexus.  Curr Drug Metab 2004, 5:95-108.
3. Schinkel AH, Jonker JW: Mammalian drug efflux transporters of
the ATP binding cassette (ABC) family: an overview.  Adv
Drug Deliv Rev 2003, 55:3-29.
4. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B: The role of ABC trans-
porters in drug resistance, metabolism and toxicity.  Curr Drug
Deliv 2004, 1:27-42.
5. Toyoda Y, Hagiya Y, Adachi T, Hoshijima K, Kuo MT, Ishikawa T:
MRP class of human ATP binding cassette (ABC) transport-
ers: historical background and new research directions.
Xenobiotica 2008, 38:833-862.
6. Sladek FM, Seidel SD: Hepatocyte nuclear factor 4alpha.  In
Nuclear Receptors and Disease Edited by: Burris T, McCabe ERB. Aca-
demic Press, London; 2001:309-361. 
7. Schrem H, Klempnauer J, Borlak J: Liver-enriched transcription
factors in liver function and development. Part I: the hepato-
cyte nuclear factor network and liver-specific gene expres-
sion.  Pharmacol Rev 2002, 54:129-158.
8. Parviz F, Matullo C, Garrison WD, Savatski L, Adamson JW, Ning G,
et al.: Hepatocyte nuclear factor 4alpha controls the develop-
ment of a hepatic epithelium and liver morphogenesis.  Nat
Genet 2003, 34:292-296.
9. Jover R, Bort R, Gomez-Lechon MJ, Castell JV: Cytochrome P450
regulation by hepatocyte nuclear factor 4 in human hepato-
cytes: a study using adenovirus-mediated antisense target-
ing.  Hepatology 2001, 33:668-675.
10. Gonzalez FJ: Regulation of hepatocyte nuclear factor 4 alpha-
mediated transcription.  Drug Metab Pharmacokinet 2008, 23:2-7.
11. Barbier O, Girard H, Inoue Y, Duez H, Villeneuve L, Kamiya A, et al.:
Hepatic expression of the UGT1A9 gene is governed by
hepatocyte nuclear factor 4alpha.  Mol Pharmacol 2005,
67:241-249.
12. Echchgadda I, Song CS, Oh T, Ahmed M, De LCI, Chatterjee B: The
xenobiotic-sensing nuclear receptors pregnane X receptor,
constitutive androstane receptor, and orphan nuclear recep-
tor hepatocyte nuclear factor 4alpha in the regulation of
human steroid-/bile acid-sulfotransferase.  Mol Endocrinol 2007,
21:2099-2111.
13. Popowski K, Eloranta JJ, Saborowski M, Fried M, Meier PJ, Kullak-
Ublick GA: The human organic anion transporter 2 gene is
transactivated by hepatocyte nuclear factor-4{alpha} and
suppressed by bile acids.  Mol Pharmacol 2005, 67:1629-1638.
14. Saborowski M, Kullak-Ublick GA, Eloranta JJ: The Human Organic
Cation Transporter 1 Gene is Transactivated by Hepatocyte
Nuclear Factor-4{alpha}.  J Pharmacol Exp Ther 2006,
317:778-785.
15. Qadri I, Hu LJ, Iwahashi M, Al Zuabi S, Quattrochi LC, Simon FR:
Interaction of hepatocyte nuclear factors in transcriptional
regulation of tissue specific hormonal expression of human
multidrug resistance-associated protein 2 (abcc2).  Toxicol
Appl Pharmacol 2009, 234:281-292.
16. Douet V, VanWart CM, Heller MB, Reinhard S, Le Saux O:
HNF4alpha and NF-E2 are key transcriptional regulators of
the murine Abcc6 gene expression.  Biochim Biophys Acta 2006,
1759:426-436.
17. Sumi K, Tanaka T, Uchida A, Magoori K, Urashima Y, Ohashi R, et al.:
Cooperative interaction between hepatocyte nuclear factor
4 alpha and GATA transcription factors regulates ATP-bind-
ing cassette sterol transporters ABCG5 and ABCG8.  Mol Cell
Biol 2007, 27:4248-4260.
18. Lim L, Zhou H, Costa RH: The winged helix transcription factor
HFH-4 is expressed during choroid plexus epithelial develop-
ment in the mouse embryo.  Proc Natl Acad Sci USA 1997,
94:3094-3099.
19. Strazielle N, Ghersi-Egea JF: Choroid plexus in the central nerv-
ous system: biology and physiopathology.  J Neuropathol Exp
Neurol 2000, 59:561-574.
20. Borlak J, Zwadlo C: Expression of drug-metabolizing enzymes,
nuclear transcription factors and ABC transporters in Caco-
2 cells.  Xenobiotica 2003, 33:927-943.
21. Niehof M, Borlak J: RSK4 and PAK5 Are Novel Candidate
Genes in Diabetic Rat Kidney and Brain.  Mol Pharmacol 2005,
67:604-611.
22. Niehof M, Borlak J: HNF4{alpha} and the Ca-Channel TRPC1
Are Novel Disease Candidate Genes in Diabetic Nephropa-
thy.  Diabetes 2008, 57:1069-1077.
23. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ: Hepato-
cyte nuclear factor 4alpha (nuclear receptor 2A1) is essential
for maintenance of hepatic gene expression and lipid home-
ostasis.  Mol Cell Biol 2001, 21:1393-1403.
24. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray
HL, et al.: Control of Pancreas and Liver Gene Expression by
HNF Transcription Factors.  Science 2004, 303:1378-1381.
25. Chiba H, Gotoh T, Kojima T, Satohisa S, Kikuchi K, Osanai M, et al.:
Hepatocyte nuclear factor (HNF)-4alpha triggers formation
of functional tight junctions and establishment of polarized
epithelial morphology in F9 embryonal carcinoma cells.  Exp
Cell Res 2003, 286:288-297.
26. Chiba H, Itoh T, Satohisa S, Sakai N, Noguchi H, Osanai M, et al.:
Activation of p21(CIP1/WAF1) gene expression and inhibi-
tion of cell proliferation by overexpression of hepatocyte
nuclear factor-4alpha.  Exp Cell Res 2005, 302:11-21.
27. Battle MA, Konopka G, Parviz F, Gaggl AL, Yang C, Sladek FM, et al.:
Hepatocyte nuclear factor 4alpha orchestrates expression of
cell adhesion proteins during the epithelial transformation of
the developing liver.  Proc Natl Acad Sci USA 2006, 103:8419-8424.
28. Torres-Padilla ME, Fougere-Deschatrette C, Weiss MC: Expression
of HNF4alpha isoforms in mouse liver development is regu-
lated by sequential promoter usage and constitutive 3' end
splicing.  Mech Dev 2001, 109:183-193.
29. Niehof M, Borlak J: EPS15R, TASP1, and PRPF3 are novel dis-
ease candidate genes targeted by HNF4alpha splice variants
in hepatocellular carcinomas.  Gastroenterology 2008,
134:1191-1202.
30. Tanaka T, Jiang S, Hotta H, Takano K, Iwanari H, Sumi K, et al.: Dys-
regulated expression of P1 and P2 promoter-driven hepato-
cyte nuclear factor-4alpha in the pathogenesis of human
cancer.  J Pathol 2006, 208:662-672.
31. Hansen SK, Parrizas M, Jensen ML, Pruhova S, Ek J, et al.: Genetic
evidence that HNF-1{alpha}-dependent transcriptional con-
trol of HNF-4{alpha} is essential for human pancreatic {beta}
cell function.  J Clin Invest 2002, 110:827-833.
32. Costa RH, Van Dyke TA, Yan C, Kuo F, Darnell JE Jr: Similarities in
transthyretin gene expression and differences in transcrip-
tion factors: liver and yolk sac compared to choroid plexus.
Proc Natl Acad Sci USA 1990, 87:6589-6593.
33. Lucas B, Grigo K, Erdmann S, Lausen J, Klein-Hitpass L, Ryffel GU:
HNF4alpha reduces proliferation of kidney cells and affects
genes deregulated in renal cell carcinoma.  Oncogene 2005,
24:6418-6431.
34. Garrison WD, Battle MA, Yang C, Kaestner KH, Sladek FM, Duncan
SA: Hepatocyte nuclear factor 4alpha is essential for embry-
onic development of the mouse colon.  Gastroenterology 2006,
130:1207-1220.
35. Loscher W, Potschka H: Role of multidrug transporters in phar-
macoresistance to antiepileptic drugs.  J Pharmacol Exp Ther
2002, 301:7-14.
36. Potschka H, Fedrowitz M, Loscher W: Multidrug resistance pro-
tein MRP2 contributes to blood-brain barrier function and
restricts antiepileptic drug activity.  J Pharmacol Exp Ther 2003,
306:124-131.
37. Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid
brain uptake by P-glycoprotein in mice.  Biochem Pharmacol
2004, 67:269-276.
38. El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, Lang-
guth P: Identification of P-glycoprotein substrates and inhibi-
tors among psychoactive compounds–implications for
pharmacokinetics of selected substrates.  J Pharm Pharmacol
2004, 56:967-975.
39. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, et al.:
The impact of P-glycoprotein on the disposition of drugs tar-
geted for indications of the central nervous system: evalua-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Molecular Biology 2009, 10:68 http://www.biomedcentral.com/1471-2199/10/68
Page 14 of 14
(page number not for citation purposes)
tion using the MDR1A/1B knockout mouse model.  Drug
Metab Dispos 2005, 33:165-174.
40. Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B: The role of ABC
transporters in drug absorption, distribution, metabolism,
excretion and toxicity (ADME-Tox).  Drug Discov Today 2008,
13:379-393.
41. Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD:
Tissue distribution and chemical induction of multiple drug
resistance genes in rats.  Drug Metab Dispos 2002, 30:838-844.
42. Choudhuri S, Cherrington NJ, Li N, Klaassen CD: Constitutive
expression of various xenobiotic and endobiotic transporter
mRNAs in the choroid plexus of rats.  Drug Metab Dispos 2003,
31:1337-1345.
43. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli
AC, et al.: Choroid plexus epithelial expression of MDR1 P
glycoprotein and multidrug resistance-associated protein
contribute to the blood-cerebrospinal-fluid drug-permeabil-
ity barrier.  Proc Natl Acad Sci USA 1999, 96:3900-3905.
44. Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G,
et al.: MDR3 P-glycoprotein, a phosphatidylcholine translo-
case, transports several cytotoxic drugs and directly inter-
acts with drugs as judged by interference with nucleotide
trapping.  J Biol Chem 2000, 275:23530-23539.
45. Wijnholds J, deLange EC, Scheffer GL, Berg DJ van den, Mol CA, van
d V, et al.: Multidrug resistance protein 1 protects the choroid
plexus epithelium and contributes to the blood-cerebrospi-
nal fluid barrier.  J Clin Invest 2000, 105:279-285.
46. Gazzin S, Strazielle N, Schmitt C, Fevre-Montange M, Ostrow JD,
Tiribelli C, et al.:  Differential expression of the multidrug
resistance-related proteins ABCb1 and ABCc1 between
blood-brain interfaces.  J Comp Neurol 2008, 510:497-507.
47. Scotto KW: Transcriptional regulation of ABC drug trans-
porters.  Oncogene 2003, 22:7496-7511.
48. Eloranta JJ, Kullak-Ublick GA: Coordinate transcriptional regula-
tion of bile acid homeostasis and drug metabolism.  Arch Bio-
chem Biophys 2005, 433:397-412.
49. Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, Yam-
azoe Y: Role of human hepatocyte nuclear factor 4alpha in
the expression of drug-metabolizing enzymes and transport-
ers in human hepatocytes assessed by use of small interfer-
ing RNA.  Drug Metab Pharmacokinet 2007, 22:287-298.
50. Dignam JD, Lebovitz RM, Roeder RG: Accurate transcription ini-
tiation by RNA polymerase II in a soluble extract from iso-
lated mammalian nuclei.  Nucleic Acids Res 1983, 11:1475-1489.
51. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Proven-
zano MD, et al.: Measurement of protein using bicinchoninic
acid.  Anal Biochem 1985, 150:76-85.
52. Kel A, Reymann S, Matys V, Nettesheim P, Wingender E, Borlak J: A
novel computational approach for the prediction of net-
worked transcription factors of aryl hydrocarbon-receptor-
regulated genes.  Mol Pharmacol 2004, 66:1557-1572.